Kallum Titchmarsh

dig a little more into some of the pricing initiatives that seem to be tracking ahead of the initial road map.

talk us through your expectations for the preclinical pipeline evolving from that smarter drug discovery

you're now comfortable with the current shape of the business? Maybe just talk through appetite for maybe more deals

any incremental ambitions to add or subtract from the business today

I think you called out $200 million of annual DSA revenue from NAMs before

which segments and geographies you've been more aggressive with on price just as we think about performance

talk us through the demand you're seeing on the service front and any stats you could just give us on the attach rate

Just any update on the reshoring theme. Maybe just talk us through those discussions with customers

maybe just talk us through how the incremental MRD data you'll now have access to could feed back into your data business

I'm curious where de-identified data is sitting in the hierarchy of needs.

So maybe some specifics on the regions and the drug categories that have been driving that growth.

I would love to hear a bit more about the underlying demand environment in APAC. Pretty strong 29% growth in Q1

just checking in on the flow of new customer conversations and conversions there. Any refreshed view on the duration of this tailwind